Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1141820170170030228
Journal of Gastric Cancer
2017 Volume.17 No. 3 p.228 ~ p.236
Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer
Park Tae-Jin

Lee Young-Joon
Jeong Sang-Ho
Choi Sang-Kyung
Jung Eun-Jung
Ju Young-Tae
Jeong Chi-Young
Park Mi-Yeong
Hah Young-Sool
Yoo Ji-Yun
Ha Woo-Song
Hong Soon-Chan
Ko Gyung-Hyuck
Abstract
Purpose: Enolase is a cytoplasmic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. The aim of this study was to investigate whether the overexpression of neuron-specific enolase (NSE) can serve as a prognostic factor in patients with gastric cancer (GC).

Materials and Methods: To assess its prognostic value in GC, NSE expression was measured by immunohistochemistry in a clinically annotated tissue microarray comprising of 327 human GC specimens. Cytoplasmic NSE expression was scored from 0 to 4, reflecting the percentage of NSE-positive cells.

Results: In terms of histology as per the World Health Organization criteria (P=0.340), there were no differences between the NSE overexpression (NSE-OE) and NSE underexpression (NSE-UE) groups. The NSE-OE group showed a significantly lower rate of advanced GC (P<0.010), lymph node metastasis (P=0.010), advanced stage group (P<0.010), cancer-related death (P<0.010), and cancer recurrence (P<0.010). Additionally, a Kaplan-Meier survival analysis revealed that the NSE-OE group had longer cumulative survival times than the NSE-UE group (log-rank test, P<0.010). However, there were no significant differences in the serum levels of NSE expression in patients with GC and healthy volunteers (P=0.280).

Conclusions: Patients with NSE overexpressing GC tissues showed better prognostic results, implying that NSE could be a candidate biomarker of GC.
KEYWORD
Stomach neoplasms, Neuron-specific enolase, Neoplasm metastasis, Prognosis
FullTexts / Linksout information
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed